Farmakoekonomické hodnocení (CEA) přípravku Vidaza (azacitidin) v terapii pacientů s myelodysplastickými syndromy v České republice – analýza nákladové efektivity a analýza dopadu na rozpočet veřejného zdravotního pojištění v letech 2013-2018.

• Title in English: Pharmacoeconomical assessment of Vidaza (azactidin) in therapy of patients with myelodysplastic syndrome in the Czech Republic – analysis of cost-effectiveness and impact on public insurance budget in 2013-2018
• Authors: BURGER Michal; ONDRÁČKOVÁ Barbora; DEMLOVÁ Regina; MUŽÍK Jan; ČERMÁK Jaroslav; JONÁŠOVÁ Anna; VOGLOVÁ Jaroslava; DUŠEK Ladislav; MÁJEK Ondřej; BRABEC Petr
• Year of publication: 2013
• MU Faculty or unit: Faculty of Medicine
• Description: Aim of the report was processing cost-affectiveness analysis and estimation of budget impact in 2013-2018 for the drug Vidaza (azactidin) from the viewpoint of healt care payers and in accordance with the methodology of the State Institute for Drug Control. Data from the MyDyS registry and the MDS Working Group at the CHS CLS JEOP were used.